Pharma
Nika Pharmaceuticals, Inc. (OTCQB: NIKA) Funding Update
HENDERSON, Nev., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA ) is continuing its ongoing negotiation with investors from Thailand, Japan, Switzerland, Luxembourg, USA, Bulgaria, and the UAE for financing of up to 50 million US dollars. The Company has seen great interest, with most investors reaching out directly to NIKA. “We are striving to select the most suitable investor and partner for NIKA, for which reason the discussions surrounding the technical details of
HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells
Human studies show that the TGF-β trap and IL-15 fusion used alone promotes expansion of progenitor CD8 + T cells and NK cells Company has incorporated the TGF-β/IL-15 moiety into the constructs of its second-generation fusion immunotherapeutics constructed with novel TRBC drug development platform MIRAMAR, Fla., Aug. 25, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel
Olympia Pharmaceuticals Introduces Polidocanol 2% Injection for Targeted Cosmetic Vein Treatment
New injection gives healthcare providers a comfortable, effective option for cosmetic spider and reticular vein therapies ORLANDO, Fla., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Olympia Pharmaceuticals , a premier FDA-registered 503B outsourcing facility and 503A pharmacy, today announced the launch of its new Polidocanol 2% (20 mg/mL) injection . Expanding Olympia’s suite of specialized vein care offerings, this injection provides qualified healthcare professionals with a formulation that gently damag
Applied Biologics Announces Acceptance of Updated CAMPX XWRAP® Clinical Trial Results for Presentation at SAWC Fall 2026
Updated analysis of 222-patient randomized controlled trial demonstrates statistically significant improvement in complete diabetic foot ulcer closure with XWRAP plus standard of care SCOTTSDALE, Ariz., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel therapies for serious diseases with significant unmet medical needs, today announced that updated results from its CAMPX randomized controlled clinical trial evaluating XWRAP® in chronic diabetic foot
Nu-Tek BioSciences to Attend BPI East 2026 in Boston, Connecting Animal-Free Culture Media Nutrients with Pharma Customer Growth Strategies
Tour Nu-Tek's state-of-the-art, 100% animal-free manufacturing facilty. Soy Peptone Soy peptones are one of the many animal-free products in Nu-Tek's raw materials portfolio. Nu-Tek will meet with pharmaceutical leadership during BioProcess International East Sept. 22-25 in Boston to discuss 100% animal-origin-free peptones and protein hydrolysates, with a focus on product quality and supply security. MINNETONKA, Minn., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Nu-Tek BioSciences, the market leader in 1
Ocugen to Participate in Upcoming September Investor and Industry Conferences
MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in September 2026. Citi 2026 Biopharma Back to School Conference Location: JW Marriott Essex House, New York City, NY Date: Wednesday, September 9, 2026 Time: 3:40–4:15 p.m. ET Forma
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
All clinical trial sites identified and CRO retained Patient screening expected to begin in October 2026, with first patient to be enrolled shortly after FOSTER CITY, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that its AURORA Phase 3 clinical trial of FASN inhibitor denifanstat in moderate to severe acne is on tr
Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments
Beyond Air to receive shares representing 19.99% of Univo's issued and outstanding share capital upon closing Beyond Air eligible to receive up to $32.5 million in development and commercial milestone payments GARDEN CITY, N.Y., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) today announced that they have entered into a definitive agreement under which UNIVO Pharmaceutical Industries Ltd (“UNIVO”) Univo Pharmaceutical Industries Ltd. ("UNIVO"), a public company whose shares ar
Cambrex High Point Completes FDA, PMDA and TGA Pre-Approval Inspections, Advancing Commercial Manufacturing Capabilities
EAST RUTHERFORD, N.J. , Aug. 25, 2026 -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the successful completion of three Pre-Approval Inspections (PAIs) at its High Point, North Carolina facility by the U.S. Food and Drug Administration (FDA), Japan s Pharmaceuticals and Medical Devices Agency (PMDA), and Australia s Therapeutic Goods Administration (TGA). The completion of all three inspections enables High Point to manufacture approved active pharmaceutical ingredients (APIs) for the United States, Japan, and Australia, establishing the facility as the newest commercial manufacturing site within the Cambrex global network.
Zealand Pharma – Notification of holding of treasury shares
Company announcement – No. 42 / 2026 Zealand Pharma – Notification of holding of treasury shares Copenhagen, Denmark, August 24, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports its notification pursuant to Section 31 of the Danish Capital Markets Act relating to its holding of treasury shares. As of 21 August 2026, the Company holds nominally 3,597,842 treasury shar
Zealand Pharma - Transactions related to share buy-back program (week 34, 2026)
Company announcement No. 41 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 34, 2026) Copenhagen, Denmark, August 24, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 34 (August 17 - August 21, 2026). The Program is carried out in accordance with Article 5 of Regu
SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
U.S. publication of a patent application covering the MDMA-N-acylethanolamines combination expands intellectual property generated through the collaboration, and provides guidance addressing clinical development considerations for psychedelic drugs, including MDMA TEL AVIV, Israel, Aug. 24, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon is eligible to receive up to $1 billion in total upfront and milestone payments from the collaboration, plus royalties on net sales THE WOODLANDS, Texas, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has earned a third $10 million milestone payment in 2026 from Novo Nordisk A/S foll
Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
WARMINSTER, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the commencement of a modified “Dutch Auction” tender offer to purchase for cancellation up to US$230 million in value of its common shares (the “Shares”) at a price of not less than US$5.00 and not more than US $5.75 per Share, less any applicable withholding taxes and without inter
VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance
Successful in vitro proof-of-concept study demonstrates the potential to create novel antibody-oligonucleotide conjugates (AOCs) by combining both parties’ technologies and expertise ZURICH, SWITZERLAND, and MARTINSRIED/MUNICH, GERMANY, Aug. 24, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in the design and development of next-generation cancer therapeutics, and Secarna Pharmaceuticals GmbH & Co. KG (“Secarna”), a company redefining the discovery and de
ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors
– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today reported the addition of Henry Gosebruch to its Board of Directors effective August 19, 2026. Mr. Gosebruch brings over 30 years of corporate strategy, business development and finance experience across the biopharmaceutical sector. “We are excited to add Henry to our Board of
TME Pharma provides update on its activities
TME Pharma provides update on its activities TME Pharma enters the final evaluation phase of advanced discussions with two potential partners for a license agreement. Discussions and potential partnership are aimed at enabling the further development of the phase2-development of flagship product NOX-A12. NOX-A12 holds FDA and EU Orphan Drug and FDA Fast Track designations in glioblastoma, supported by recent peer-reviewed publication in Nature Communications . With estimated yearly peak sales po
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
New York, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 307,692 shares of common stock in a registered direct offering. The gross proceeds of the offering are approximately $2.0 million (the "Offering"). D. Boral Capital LLC is acti
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
REYKJAVIK, Iceland, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical (TWSE Stock Code: 1795) covering two of Alvotech’s candidates in the United States and selected Asian markets: AVT34, a proposed biosimilar to Imfinzi® (durvalumab), and AVT87, a proposed
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
REYKJAVIK, ICELAND (August 21, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical (TWSE Stock Code: 1795) covering two of Alvotech’s candidates in the United States and selected Asian markets: AVT34, a proposed biosimilar to Imfinzi® (durvalumab), and AVT87, a proposed biosimilar to H
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced plans to commence a modified “Dutch Auction” tender offer (the “Offer”) to repurchase up to US$230 million of its common shares at a purchase price of not less than US$5.00 per share and not more than US$5.75 per share, in cash, less any applicable withholding taxes and without inter
PharmAla Biotech Provides Corporate Update: U.S. Patent Granted Covering Novel Enantioselective Processes, Decision on APA-01, and Engagement of Canaccord Genuity as Exclusive Investment Banking Partner
U.S. Patent 12,679,817, covering novel processes for preparing the (R)- and (S)-enantiomers of MDMA and MBDB, granted to PharmAla by the US Patent and Trademark Office (USPTO) PharmAla has exercised its option to cancel the proposed licensing of APA-01 to Restora Neurosciences, and will evaluate in-house and co-development pathways Canaccord Genuity LLC has been engaged as exclusive financial advisor and placement agent TORONTO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“
Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline
PARIS, FRANCE, 21 AUGUST 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company adding late-stage MDM2 inhibitor navtemadlin in Phase III clinical development in myelofibrosis. About navtemadlin Navtemadlin is an investigational oral MDM2 inhibitor being developed as an add-on therapy to ruxolitinib for patients with myelofibrosis who have a suboptimal response to ruxolitinib. The Phase III POIE
NurExone Announces Closing of C$1,066,078 Private Placement
TORONTO, and HAIFA, Israel, Aug. 21, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that it has closed a non-brokered private placement of 1,938,326 units (“ Units ”) at a price of C$0.55 per Unit for aggregate gross proceeds of approximately C$1,066,078.02 (the “ Offering ”), subject to final acceptance of the TSX Venture E
BioSyent Releases Financial Results for Q2 and H1 2026
MISSISSAUGA, Ontario, Aug. 20, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its consolidated financial results for the three months (Q2), six months (H1), and trailing twelve months (TTM) ended June 30, 2026. Key highlights include: (CAD) Q2 2026 % Change vs. Q2 2025 H1 2026 % Change vs. H1 2025 TTM Jun 30, 2026 % Change vs. TTM Jun 30, 2025 Pharmaceutical Sales 11,110,365 +14% 21,913,472 +7% 42,325,508 +11% Oral Health Sales 8,224,402 n/a 11,209,375 n/a 11
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on August 15, 2026 to 13 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordan
Sino Biopharmaceutical Limited Unveils New Global Brand, SBP Group, to Accelerate International Expansion
HONG KONG , Aug. 19, 2026 -- Sino Biopharmaceutical Limited (HKEX: 01177), a leading innovation-driven pharmaceutical company in China, announced the launch of its new global brand, SBP Group, during its interim results meeting. SBP stands for Science, Breakthroughs and Patients: Science is where the company starts; breakthroughs are what it pursues; patients are why it does what it does. This philosophy aligns with the Company s mission, Science for a Healthier World.
ArkBio's RSV Antiviral Drug Ziresovir Receives FDA Approval for Phase II Clinical Trial
SHANGHAI , Aug. 14, 2026 -- Shanghai Ark Biopharmaceutical Co., Ltd. ( ArkBio ) today announced that the U.S. Food and Drug Administration (FDA) has approved ziresovir (AK0529) for a phase II clinical trial in the severely ill RSV infected infant patients, including the ones in pediatric intensive care unit (PICU). Severe RSV Infection: An Urgent Unmet Need in PICU RSV is the leading pathogen of lower respiratory tract infections (LRTIs) in infants and young children globally, causing approximately 33 million LRTI cases, 3.6 million hospitalizations, and more than 100,000 deaths annually. Severely ill RSV infected infants often require admission to the PICU for intensive care such as respiratory support, with rapid disease progression, high risk and a heavy medical burden. There is currently no approved RSV-specific antiviral therapy worldwide; clinical management remains limited to symptomatic and supportive care, such as oxygenation, leaving an urgent unmet need for effective antiviral treatment in hospitalized RSV infected patients with severe diseases.
Axtria to Build Industry's Largest Pharma-Specific AI Engineering Team, Scaling to 1,000 by December 2026
NEW DELHI , Aug. 13, 2026 -- Axtria Inc. , a global leader in AI-first data analytics solutions for the life sciences industry, today announced plans to expand its Forward Deployed Engineering (FDE) organization to 1,000 engineers by December 2026 , creating the industry s largest pharma-specific AI engineering team. The expansion represents one of Axtria s largest investments in AI talent development to date and reflects growing customer demand for engineers who can deploy, scale, and operationalize enterprise AI across commercial, medical, and market access functions.
ArkBio Announces China IND Approval for its Antiviral Drug-Fc Conjugate (AFC) Candidate AK0406 for Influenza Prophylaxis
SHANGHAI , Aug. 13, 2026 -- Shanghai Ark Biopharmaceutical Co., Ltd. ( ArkBio ) today announced that the Investigational New Drug (IND) application for AK0406 injection, the company s first long-acting antiviral drug Fc conjugate (AFC) candidate for influenza prophylaxis, has been approved by the National Medical Products Administration (NMPA) of China, making AK0406 the first influenza AFC drug to enter clinical development in China.
Cambrex Milan Celebrates 80th Anniversary with Construction of New $30 Million R&D Facility
EAST RUTHERFORD, N.J. , Aug. 11, 2026 -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the start of construction on a new research and development (R&D) facility at its Milan, Italy site. This 30 million investment will add advanced analytical development and process R&D capabilities, alongside upgrades to multiple production plants, reinforcing Cambrex s commitment to supporting the pharmaceutical industry s most complex small molecule development.
NYSE Content Update: Goldman Sachs Asset Management Launches Two New ETFs
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK , Aug. 10, 2026 -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today s NYSE Pre-market update for market insights before trading begins. Kristen Scholer delivers the pre-market update on August 10th The S&P 500 looks to build off Friday s record close as investors track the latest developments in the Middle East. Goldman Sachs Asset Management s Lindsay Rosner will join NYSE Live as her firm brings new offerings to the NYSE community. GCPB ETF focuses on new types of core plus bond exposure. GINC ETF aims to balance income potential and diversification. LifeMine Therapeutics CEO Greg Verdine will join NYSE Live to discuss the biopharmaceutical firm s latest achievements. Announced raise of 263 million late last week. Firm is accelerating the clinical development of its lead program, LIFE-001, which is designed to prevent organ transplant rejection.
Utility Global Names Robert Lane Chief Financial Officer to Drive Commercialization at Scale
Capital markets veteran joins company to fuel next phase of rapid growth HOUSTON , Aug. 5, 2026 -- Utility Global ( Utility ), a global company enabling the economic industrial decarbonization of heavy industries, today announced the appointment of Robert Lane as Chief Financial Officer. Lane joins Utility at a defining time as the company pivots into its commercialization phase. Lane has a proven record of scaling organizations and guiding companies through rapid commercial growth. He brings more than three decades of financial leadership across energy, industrial and growth-stage companies, most recently as CFO of Quva Pharma, where he led finance, accounting, IT and treasury functions through a period of process modernization and liquidity improvement. Previously, as Executive Vice President and CFO of Sunnova Energy International, he helped lead the company s Initial Public Offering (IPO) and closed more than 10 billion in tax equity, debt and equity financing to fund its growth. At Spark Energy, Lane helped lead the company through several acquisitions and integrations, simplified the corporate structure, and led creative and innovative financing strategies. At Emerge Energy Services, he guided the company through its IPO and capital expansion while significantly lowering the cost of debt. Across his career, Lane has led dozens of capital markets transactions collectively worth tens of billions of dollars and has a proven track record of building the financial infrastructure to support fast-growing companies to help them scale.
SVKM's NMIMS Horizon Expands AI-Embedded Learning to Undergraduate Education
Curriculum-Embedded AI learning to be introduced across undergraduate programmes at NMIMS campuses MUMBAI, India , Aug. 5, 2026 -- Building on the successful implementation of NMIMS Horizon in management education, SVKM s Narsee Monjee Institute of Management Studies (NMIMS) Deemed-to-be University officially extended the initiative to undergraduate programmes on 3 August, 2026. The next phase brings AI-focused learning to the Schools of Engineering, Science, Pharmacy, and Commerce as part of the University s vision to integrate emerging technologies into higher education.
Piramal Pharma Solutions Expands Peptide API Facility with Advanced Spray Drying Suite
Piramal Pharma Solutions has added a new spray drying suite with Band 5 containment capacity at its dedicated peptide facility in Turbhe, India, equipped with its own air handling units, nitrogen supply, and control systems. The new suite empowers Turbhe to support the formulation of challenging molecules, including peptides, HPAPIs, and other biomolecules. MUMBAI, India , Aug. 4, 2026 -- Piramal Pharma Solutions ( PPS ), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), has launched a state-of-the-art spray drying suite at its dedicated peptide development and manufacturing facility in Turbhe, India. This strategic expansion enables PPS to address the complex formulation challenges associated with peptides and other complex molecules and support the growing demand for these innovative molecules.
Enzene Launches NeX™, a Comprehensive Suite of Solutionsto Enable Cost-Efficient, High-Yielding Local Biomanufacturing
PUNE, India , Aug. 3, 2026 -- Enzene, a leading global continuously innovative development and manufacturing organization (CIDMO ), today announced the launch of NeX , a transformative end-to-end partnership model that enables governments, institutions, and biopharma organizations to establish world-class biomanufacturing capabilities wherever they need them. Built on the company s proven EnzeneX fully connected continuous manufacturing (FCCM ) platform, NeX delivers a turnkey, scalable, and sustainable way to make state-of-the-art innovation in biologics manufacturing transportable, close to patients and supply chains, and without the prohibitive capital burden of conventional fed batch facilities. By enabling local FCCM based manufacturing, governments can significantly expand patient affordability and access to life saving biologics.
Chandigarh University's Biotechnology & Pharmacy Students Secure 178 Placements with Leading Pharmaceutical and Biotechnology Companies
Leading national & global companies like Sun Pharma, GSK, Medtronic India, Serum Institute of India recruit Chandigarh University students CHANDIGARH, India , July 30, 2026 -- The rapid growth of Biotechnology, Pharmaceutical Sciences and allied healthcare fields has triggered a high demand for professionals equipped with specialized knowledge, practical skills and industry exposure. To meet this growing demand, Chandigarh University has integrated experiential learning model into its Biotechnology and Pharmaceutical Sciences programmes with 178 students securing placements and 261 students gaining industry internships in leading pharmaceutical companies, reputed healthcare institutions (hospitals) and life sciences organisations over the past three years.
Continuity Biosciences Appoints Vicky Papoutsis to Board of Directors
Business development and corporate strategy executive joins Board as Company advances its clinical programs and partnering activity BRADENTON, Fla. , July 30, 2026 -- Continuity Biosciences today announced the appointment of Vicky Papoutsis to its Board of Directors. Vicky brings more than 25 years of biopharmaceutical business development and corporate strategy experience to the Board as the Company advances its clinical and preclinical programs and expands its partnering activity.
Piramal Pharma Limited Announces Results for Q1 FY27
MUMBAI, India , July 29, 2026 -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the First Quarter (Q1) ended 30 th June 2026. Consolidated Financial Highlights (in Crores or as stated) Particulars Q1FY27 Q1FY26 % Change Revenue from Operations 2,270 1,934 17 % CDMO 1,187 997 19 % CHG 743 637 17 % PCH 347 302 15 % EBITDA 285 165 72 % EBITDA Margin 12.5 % 8.5 % PAT (before exceptional item) (69) (102) 32 % Exceptional Item - 21 NM PAT (after exceptional item) (69) (82) 15 %
Amity Institute of Pharmacy, Amity University Madhya Pradesh Earns Prestigious 'A' Grade from Quality Council of India-National Accreditation Board for Education and Training (QCI-NABET), under the aegis of the Pharmacy Council of India
Only Pharmacy Institution in Madhya Pradesh to Receive the Distinction; Among Just 64 Institutions Nationwide GWALIOR, India , July 29, 2026 -- Amity Institute of Pharmacy (AIP), Amity University Madhya Pradesh, has achieved a significant milestone in academic excellence by being awarded the prestigious A Grade by the Quality Council of India-National Accreditation Board for Education and Training (QCI-NABET), conducted under the aegis of the Pharmacy Council of India (PCI), following a comprehensive institutional inspection and evaluation.